Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$541.08-0.28%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · MDGL
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | — | 958.4 | 180.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — | — | 0.1 | — | — | — |
| Total Revenues | — | — | 180.1 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — | — | — | 0.1 | — | — | — |
| Cost of Revenues | — | — | 6.2 | 0.0 | 0.0 | — | — | — | — | — | — | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 1,007.0 | 813.8 | 435.1 | 108.1 | 48.1 | — | — | — | — | — | — | — | — | — | — | — |
| Operating Income | (322.6) | (300.1) | (497.9) | (380.5) | (293.6) | (242.5) | (206.7) | (95.0) | (40.7) | (32.1) | (25.2) | (3.2) | (84.0) | (87.6) | (60.9) | (45.4) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | 22.3 | 14.7 | 12.7 | 4.0 | 0.0 | 0.0 | — | 1.2 | 1.2 | 1.2 | — | — | — | — | — |
| Interest & Investment Income | 35.1 | 37.4 | 46.7 | 19.6 | 2.2 | 0.4 | — | — | — | — | — | — | — | — | — | — |
| Net Interest Expenses | — | — | — | (6.9) | 1.8 | (0.4) | — | — | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — | — | — | — | — | — | — |
| Net Income | ||||||||||||||||
| Net Income | (325.1) | (288.3) | (465.9) | (373.6) | (295.3) | (241.8) | (202.2) | (83.9) | (32.8) | (31.2) | (26.4) | (6.8) | (86.2) | (90.2) | (62.8) | (47.4) |
| Per Share | ||||||||||||||||
| Basic EPS | (11.15) | (12.85) | (21.90) | (17.33) | (17.23) | (14.63) | (13.09) | — | — | — | — | — | — | — | — | (1.00) |
| Diluted EPS | (11.15) | (12.85) | (21.90) | (17.33) | (17.23) | (14.63) | (13.09) | — | — | — | — | — | — | — | — | (1.00) |
| Basic Weighted Avg Shares | 29.1 | 22.4 | 21.3 | 21.6 | 17.1 | 16.5 | 15.4 | — | — | — | — | — | — | — | — | 47.2 |
| Diluted Weighted Avg Shares | 29.1 | 22.4 | 21.3 | 21.6 | 17.1 | 16.5 | 15.4 | — | — | — | — | — | — | — | — | 47.2 |
| Supplemental | ||||||||||||||||
| EBITDA | — | (298.6) | (496.8) | (380.0) | (293.1) | (242.1) | (206.2) | (94.9) | (40.6) | (32.0) | (25.2) | (2.6) | (83.3) | (87.0) | (60.2) | (44.0) |
| EBIT | (322.6) | (300.1) | (497.9) | (380.5) | (293.6) | (242.5) | (206.7) | (95.0) | (40.7) | (32.1) | (25.2) | (3.2) | (84.0) | (87.6) | (60.9) | (45.4) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.